Clinical trials: Unresectable Cancer
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Stomach Neoplasms
Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Stomach Neoplasms.
- Trial name
- IRE (NCT02430636)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Gastrointestinal Neoplasms, Pancreatic Neoplasms
A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas
Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Involved-field irradiation using 4-15 MV photons; plus Gemcitabine, NSC-613327.
- Trial name
- NCT00001431
- Testing
- gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Disseminated Neuroblastoma, Localized Unresectable Neuroblastoma
R(+)XK469 in Treating Patients With Advanced Neuroblastoma
This phase I trial is studying the side effects and best dose of R(+)XK469 in treating patients with advanced neuroblastoma. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop…
- Conditions
- Disseminated Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00028522
- Testing
- R(+)XK469
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
This study is an early access program of 'Nexavar post-marketing surveillance (PMS) for renal cell carcinoma (RCC) in Japan' which is a regulatory, local prospective and observational study for patients with unresectable or…
- Trial name
- NCT01412671
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 117 people
- Sponsor
- Bayer
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by…
- Conditions
- Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8
- Trial name
- NCT06900595
- Testing
- Biospecimen Collection, Cabozantinib, Cemiplimab
- Where
- 81 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma, Malignant
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
- Trial name
- NCT05324436
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma
Study of DNA in Blood Samples From Patients With Neuroblastoma
This research trial studies is deoxyribonucleic acid (DNA) in blood samples from patients with neuroblastoma. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that…
- Conditions
- Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma
- Trial name
- NCT00898391
- Testing
- laboratory biomarker analysis, polymerase chain reaction, polyacrylamide gel electrophoresis
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- Children's Oncology Group
Esophageal Diseases
Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered
The aim of this post-market clinical follow-up study is to evaluate the continued safety and performance of the marketed Evolution® Esophageal Stent System (Partially- and Fully Covered).
- Trial name
- NCT05182255
- Testing
- Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered
- Where
- 5 sites in Germany, Spain and 1 more
- Volunteers
- 127 people
- Sponsor
- Cook Research Incorporated
Melanoma
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma.
- Trial name
- NCT01067066
- Testing
- TPI 287, Temodar (Temozolomide)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Neoplasm, Liver Neoplasm
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan.
- Conditions
- Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis
- Trial name
- NCT00001576
- Testing
- Melphalan, Floxuridine, Leucovorin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Dedifferentiated Liposarcoma
Selinexor in Advanced Liposarcoma
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma.
- Trial name
- SEAL (NCT02606461)
- Testing
- Selinexor
- Where
- 71 sites in United States, Belgium and 8 more
- Volunteers
- 342 people
- Sponsor
- Karyopharm Therapeutics Inc
Sarcoma, Sarcoma Metastatic
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body.
- Trial name
- NCT04076579
- Testing
- Olaparib, Trabectedin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
There is no effective standard treatment for fibrolamellar liver cancer that cannot be removed by surgery. The investigators want to find out what effects, good and/or bad, 3 drugs called letrozole, leuprolide and everolimus will…
- Trial name
- NCT01642186
- Testing
- everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Transarterial Chemoembolization
TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- Thalen (NCT04531228)
- Testing
- TACE-HAIC plus lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yunfei Yuan
Neuroblastoma
Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and predict how patients will respond to treatment.
- Trial name
- NCT01520233
- Testing
- RNA analysis, gene expression analysis, laboratory biomarker analysis
- Volunteers
- 100 people
- Sponsor
- Children's Oncology Group
Melanoma
PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma
Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.
- Trial name
- NCT02492815
- Where
- 17 sites in United States, Austria and 14 more
- Volunteers
- 1,773 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
This phase II trial studies how well pembrolizumab and interferon gamma-1b work in treating patients with stage IB-IVB mycosis fungoides and Sezary syndrome that has come back (relapsed) or has not responded to previous treatment…
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome
- Trial name
- NCT03063632
- Testing
- Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00089258
- Testing
- beta-glucan, monoclonal antibody 3F8, sargramostim
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center